Developer docs
API playgroundTry for free, no card

Search company profiles

Kazia Therapeutics

Full company profile

uuid0002eil

Namestring
Kazia Therapeutics
Legal namestring
Kazia Therapeutics Limited
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Kazia Therapeutics Limited is an Australia-incorporated, Nasdaq-listed (KZIA) clinical-stage oncology biotechnology company headquartered in Sydney. Founded in 2016 as a spin-out from Novogen, the company develops drug candidates targeting cancers that are poorly served by existing therapies, including glioblastoma, triple-negative breast cancer (TNBC), renal cell carcinoma, liver cancer, and rare pediatric brain tumors such as DIPG and AT/RT. The pipeline is anchored by paxalisib (GDC-0084), a brain-penetrant dual PI3K/mTOR inhibitor with FDA Rare Pediatric Disease and Orphan Drug designations, currently in Phase 1b/2 development. EVT801, a small-molecule VEGF receptor inhibitor for renal and liver cancers, is in Phase 1 trials. The preclinical pipeline has been expanded through the in-licensing of NDL2, a first-in-class nuclear PD-L1 protein degrader showing 49-73% tumor reduction in TNBC models, and MSETC, a SETDB1-targeted epigenetic bicyclic peptide platform acquired from QIMR Berghofer in April 2026. First-in-human trials for NDL2 are planned for 2027.

The company operates a pre-revenue business model, funding development through private placements and equity raises (over $54 million in 2025-2026 alone) rather than product sales, with anticipated future revenue from licensing deals or post-approval commercialization. Its go-to-market approach is enterprise-focused: scientific engagement through peer-reviewed publications and major oncology conferences (AACR, ASCO, Society for Neuro-Oncology), regulatory interaction through Type C meetings and the FDA's Project FrontRunner pathway, and clinical-trial-based drug distribution across US, Canadian, Australian, and European sites. The company previously traded on the ASX but delisted in late 2023 to consolidate on Nasdaq, where it regained full compliance following a $50 million private placement in December 2025. Leadership was refreshed in 2026 with the appointments of Dr. Sudha Rao (CSO, April 2026) and James Levine (CFO, June 2026), alongside CEO Dr. John Friend (appointed May 2023).

Short descriptiontext

Kazia Therapeutics is a clinical-stage Australian oncology biotech developing brain-penetrant PI3K/mTOR inhibitor paxalisib for glioblastoma and TNBC, plus preclinical programs in protein degradation and epigenetic immunotherapy, targeting cancers poorly served by existing therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHornsby, Australia
HQ citystring
Hornsby
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, glioblastoma therapeutics, PI3K inhibitor research, protein degradation therapy, cancer epigenetics
Industry2 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeLicensing Royalties
Description

Kazia Therapeutics is a pre-revenue clinical-stage biotech company developing oncology drugs. The company has no commercialized products and does not generate product revenue. Funding comes from private placements, institutional financing, and potential future partnerships or licensing deals.

finance.yahoo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Paxalisib
Description

Lead brain-penetrant PI3K/mTOR inhibitor being developed for glioblastoma, triple negative breast cancer, and other oncology indications

manilatimes.net
+3 more records
Core offering1 text field

Kazia Therapeutics is a clinical-stage oncology company developing proprietary drug candidates for cancers with significant unmet medical need. Its portfolio centers on Paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor for glioblastoma and triple-negative breast cancer, alongside the EVT801 VEGF receptor inhibitor, the NDL2 nuclear PD-L1 protein degrader, and the MSETC SETDB1-targeted epigenetic platform acquired from QIMR Berghofer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • NDL2 reduced primary tumor volume by 49% as monotherapy and 73% in combination with anti-PD-1 therapy in TNBC models
+4 more records
Product overview1 text field

Kazia Therapeutics is a clinical-stage oncology company developing a pipeline of cancer drug candidates. The company's portfolio includes the lead asset Paxalisib (a brain-penetrant PI3K/mTOR inhibitor) in clinical development for glioblastoma and triple-negative breast cancer, EVT801 in clinical trials for advanced cancers, and preclinical programs including NDL2 (a nuclear PD-L1 protein degrader) and MSETC (a SETDB1-targeted epigenetic platform). The company focuses on treatments for brain cancer, renal cancer, and liver cancer that are poorly served by existing therapies.

Product and service4 records
1Paxalisib
CategoryOncology Therapeutics
Description

Brain-penetrant dual PI3K/mTOR inhibitor being developed for glioblastoma, triple-negative breast cancer, and other oncology indications including pediatric brain cancers such as DIPG and AT/RT. It is Kazia's lead clinical-stage drug candidate.

2EVT801
CategoryOncology Therapeutics
Description

VEGF receptor inhibitor candidate in clinical development for advanced renal cell carcinoma and liver cancers. A small-molecule oncology therapy intended to address tumor angiogenesis.

3NDL2
CategoryOncology Therapeutics
Description

First-in-class nuclear PD-L1 protein degrader designed to address immunotherapy resistance and metastatic progression, with preclinical TNBC data showing 49% primary tumor reduction as monotherapy and 73% in combination with anti-PD-1 therapy.

4MSETC
CategoryOncology Therapeutics
Description

Lead candidate bicyclic peptide from the SETDB1-targeted epigenetic drug development platform in-licensed from QIMR Berghofer, designed to restore immune signaling in tumors resistant to immunotherapy.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-13
Description

Kazia Therapeutics in-licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer for approximately $1.39 million upfront, plus a tiered revenue-sharing structure with no clinical or regulatory milestone obligations. The platform includes lead candidate MSETC, a bicyclic peptide designed to restore immune signaling in tumors resistant to immunotherapy. Dr. Sudha Rao, CSO, is the scientific originator of this platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ongoing collaboration with QIMR Berghofer for epigenetic platform development. The platform targets SETDB1 proteins to restore immune signaling in immunotherapy-resistant tumors. Combined cost to advance both SETDB1 and PD-L1 degrader programs to IND readiness expected to be approximately $6 million over 18 months, with substantial portion eligible for Australian R&D tax incentives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for development of MSETC and follow-on compounds from the SETDB1 program. The transaction extends Kazia's oncology strategy alongside existing paxalisib program and PD-L1 platform.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology biotech developing brain-penetrant therapies for glioblastoma multiforme (berubicin). Directly comparable clinical-stage GBM-focused peer with similar patient population and regulatory pathway.

TypeDirect peer
Description

Commercial-stage oncology company whose Tumor Treating Fields (TTFields) therapy is approved for glioblastoma. Direct GBM treatment peer operating in the same indication Kazia's lead asset targets.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing personalized dendritic cell therapies (DCVax) for glioblastoma and other solid tumors. Closely comparable clinical-stage GBM peer with similar regulatory pathway.

TypeDirect peer
Description

Clinical-stage oncology company with biomarker-driven drug development programs including glioblastoma. Comparable clinical-stage biotech pursuing novel oncology mechanisms with similar platform strategy.

TypeEmerging player
Description

Clinical-stage biotech pioneering targeted protein degradation (PROTAC platform). Directly comparable to Kazia's NDL2 nuclear PD-L1 degrader program given shared focus on protein degradation oncology modalities.

TypeEmerging player
Description

Clinical-stage oncology company developing targeted phospholipid drug conjugates. Comparable clinical-stage oncology profile and former employer of Kazia's CEO Dr. John Friend.

TypeEmerging player
Description

Clinical-stage oncology company developing onvansertib for KRAS-mutated cancers. Comparable clinical-stage small-cap oncology peer and former employer of Kazia's CFO James Levine.

TypeEmerging player
Description

Clinical-stage oncology company developing gene-therapy-based treatments for solid tumors including GBM (ofra-vec). Comparable clinical-stage oncology profile with overlapping GBM indication focus.

TypeEmerging player
Description

Clinical-stage cell and gene therapy company with multiple oncology programs including GBM (MB-101). Comparable clinical-stage small-cap biotech profile running several parallel oncology programs.

TypeEmerging player
Description

Clinical-stage biotech developing targeted protein degradation therapies using heterobifunctional small molecules. Directly relevant peer for Kazia's NDL2 nuclear PD-L1 degrader given shared focus on oncology protein degradation.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kazia Therapeutics

Oncology Therapeuticskaziatherapeutics.com

Kazia Therapeutics is a clinical-stage Australian oncology biotech developing brain-penetrant PI3K/mTOR inhibitor paxalisib for glioblastoma and TNBC, plus preclinical programs in protein degradation and epigenetic immunotherapy, targeting cancers poorly served by existing therapies.

What Kazia Therapeutics does

Kazia Therapeutics Limited is an Australia-incorporated, Nasdaq-listed (KZIA) clinical-stage oncology biotechnology company headquartered in Sydney. Founded in 2016 as a spin-out from Novogen, the company develops drug candidates targeting cancers that are poorly served by existing therapies, including glioblastoma, triple-negative breast cancer (TNBC), renal cell carcinoma, liver cancer, and rare pediatric brain tumors such as DIPG and AT/RT. The pipeline is anchored by paxalisib (GDC-0084), a brain-penetrant dual PI3K/mTOR inhibitor with FDA Rare Pediatric Disease and Orphan Drug designations, currently in Phase 1b/2 development. EVT801, a small-molecule VEGF receptor inhibitor for renal and liver cancers, is in Phase 1 trials. The preclinical pipeline has been expanded through the in-licensing of NDL2, a first-in-class nuclear PD-L1 protein degrader showing 49-73% tumor reduction in TNBC models, and MSETC, a SETDB1-targeted epigenetic bicyclic peptide platform acquired from QIMR Berghofer in April 2026. First-in-human trials for NDL2 are planned for 2027.

The company operates a pre-revenue business model, funding development through private placements and equity raises (over $54 million in 2025-2026 alone) rather than product sales, with anticipated future revenue from licensing deals or post-approval commercialization. Its go-to-market approach is enterprise-focused: scientific engagement through peer-reviewed publications and major oncology conferences (AACR, ASCO, Society for Neuro-Oncology), regulatory interaction through Type C meetings and the FDA's Project FrontRunner pathway, and clinical-trial-based drug distribution across US, Canadian, Australian, and European sites. The company previously traded on the ASX but delisted in late 2023 to consolidate on Nasdaq, where it regained full compliance following a $50 million private placement in December 2025. Leadership was refreshed in 2026 with the appointments of Dr. Sudha Rao (CSO, April 2026) and James Levine (CFO, June 2026), alongside CEO Dr. John Friend (appointed May 2023).

Kazia Therapeutics firmographics

Firmographics
Name
Kazia Therapeutics
Legal name
Kazia Therapeutics Limited
Website
https://kaziatherapeutics.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Kazia Therapeutics is a clinical-stage Australian oncology biotech developing brain-penetrant PI3K/mTOR inhibitor paxalisib for glioblastoma and TNBC, plus preclinical programs in protein degradation and epigenetic immunotherapy, targeting cancers poorly served by existing therapies.
Ownership category
akta.pro rank

Kazia Therapeutics industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Oncology drug development
  • Glioblastoma therapeutics
  • PI3K inhibitor research
  • Protein degradation therapy
  • Cancer epigenetics

Where Kazia Therapeutics is headquartered

Location

Headquarters

HQ city
Hornsby
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Kazia Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Development and Commercialization: Kazia Therapeutics is a pre-revenue clinical-stage biotech company developing oncology drugs. The company has no commercialized products and does not generate product revenue. Funding comes from private placements, institutional financing, and potential future partnerships or licensing deals.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Kazia Therapeutics product offering

Product offering

Core offering

Kazia Therapeutics is a clinical-stage oncology company developing proprietary drug candidates for cancers with significant unmet medical need. Its portfolio centers on Paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor for glioblastoma and triple-negative breast cancer, alongside the EVT801 VEGF receptor inhibitor, the NDL2 nuclear PD-L1 protein degrader, and the MSETC SETDB1-targeted epigenetic platform acquired from QIMR Berghofer.

Product overview

Kazia Therapeutics is a clinical-stage oncology company developing a pipeline of cancer drug candidates. The company's portfolio includes the lead asset Paxalisib (a brain-penetrant PI3K/mTOR inhibitor) in clinical development for glioblastoma and triple-negative breast cancer, EVT801 in clinical trials for advanced cancers, and preclinical programs including NDL2 (a nuclear PD-L1 protein degrader) and MSETC (a SETDB1-targeted epigenetic platform). The company focuses on treatments for brain cancer, renal cancer, and liver cancer that are poorly served by existing therapies.

Differentiator

Problem solved

Functional benefit

Brands

  • Paxalisib: Lead brain-penetrant PI3K/mTOR inhibitor being developed for glioblastoma, triple negative breast cancer, and other oncology indications
  • NDL2
  • MSETC
  • EVT801

Products and services

  • Paxalisib Brain-penetrant dual PI3K/mTOR inhibitor being developed for glioblastoma, triple-negative breast cancer, and other oncology indications including pediatric brain cancers such as DIPG and AT/RT. It is Kazia's lead clinical-stage drug candidate.
  • EVT801 VEGF receptor inhibitor candidate in clinical development for advanced renal cell carcinoma and liver cancers. A small-molecule oncology therapy intended to address tumor angiogenesis.
  • NDL2 First-in-class nuclear PD-L1 protein degrader designed to address immunotherapy resistance and metastatic progression, with preclinical TNBC data showing 49% primary tumor reduction as monotherapy and 73% in combination with anti-PD-1 therapy.
  • MSETC Lead candidate bicyclic peptide from the SETDB1-targeted epigenetic drug development platform in-licensed from QIMR Berghofer, designed to restore immune signaling in tumors resistant to immunotherapy.

Quantifiable outcome

  • NDL2 reduced primary tumor volume by 49% as monotherapy and 73% in combination with anti-PD-1 therapy in TNBC models
  • +4 more outcomes

Companies that use Kazia Therapeutics

Customer profile

Segments4 records

Ideal customer profiles2 records

Kazia Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Kazia Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • QIMR Berghofer Medical Research InstitutecoreStrategic or Co-development Partner · 13 April 2026Kazia Therapeutics in-licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer for approximately $1.39 million upfront, plus a tiered revenue-sharing structure with no clinical or regulatory milestone obligations. The platform includes lead candidate MSETC, a bicyclic peptide designed to restore immune signaling in tumors resistant to immunotherapy. Dr. Sudha Rao, CSO, is the scientific originator of this platform.
  • QIMR Berghofer Medical Research InstitutecoreStrategic or Co-development PartnerOngoing collaboration with QIMR Berghofer for epigenetic platform development. The platform targets SETDB1 proteins to restore immune signaling in immunotherapy-resistant tumors. Combined cost to advance both SETDB1 and PD-L1 degrader programs to IND readiness expected to be approximately $6 million over 18 months, with substantial portion eligible for Australian R&D tax incentives.
  • QIMR Berghofer Medical Research InstitutecoreStrategic or Co-development PartnerPartnership for development of MSETC and follow-on compounds from the SETDB1 program. The transaction extends Kazia's oncology strategy alongside existing paxalisib program and PD-L1 platform.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Kazia Therapeutics competitors and assessment

Company assessment

Direct peers

  • CNS Pharmaceuticals: Clinical-stage oncology biotech developing brain-penetrant therapies for glioblastoma multiforme (berubicin). Directly comparable clinical-stage GBM-focused peer with similar patient population and regulatory pathway.
  • Novocure: Commercial-stage oncology company whose Tumor Treating Fields (TTFields) therapy is approved for glioblastoma. Direct GBM treatment peer operating in the same indication Kazia's lead asset targets.
  • Northwest Biotherapeutics: Clinical-stage immuno-oncology company developing personalized dendritic cell therapies (DCVax) for glioblastoma and other solid tumors. Closely comparable clinical-stage GBM peer with similar regulatory pathway.
  • Denovo Biopharma: Clinical-stage oncology company with biomarker-driven drug development programs including glioblastoma. Comparable clinical-stage biotech pursuing novel oncology mechanisms with similar platform strategy.

Emerging players

  • Arvinas: Clinical-stage biotech pioneering targeted protein degradation (PROTAC platform). Directly comparable to Kazia's NDL2 nuclear PD-L1 degrader program given shared focus on protein degradation oncology modalities.
  • Cellectar Biosciences: Clinical-stage oncology company developing targeted phospholipid drug conjugates. Comparable clinical-stage oncology profile and former employer of Kazia's CEO Dr. John Friend.
  • Cardiff Oncology: Clinical-stage oncology company developing onvansertib for KRAS-mutated cancers. Comparable clinical-stage small-cap oncology peer and former employer of Kazia's CFO James Levine.
  • VBL Therapeutics: Clinical-stage oncology company developing gene-therapy-based treatments for solid tumors including GBM (ofra-vec). Comparable clinical-stage oncology profile with overlapping GBM indication focus.
  • Mustang Bio: Clinical-stage cell and gene therapy company with multiple oncology programs including GBM (MB-101). Comparable clinical-stage small-cap biotech profile running several parallel oncology programs.
  • Kymera Therapeutics: Clinical-stage biotech developing targeted protein degradation therapies using heterobifunctional small molecules. Directly relevant peer for Kazia's NDL2 nuclear PD-L1 degrader given shared focus on oncology protein degradation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Kazia Therapeutics social profiles

Digital presence

Kazia Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kazia Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Kazia Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kazia Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kazia Therapeutics

What does Kazia Therapeutics do?

Kazia Therapeutics is a clinical-stage oncology company developing proprietary drug candidates for cancers with significant unmet medical need. Its portfolio centers on Paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor for glioblastoma and triple-negative breast cancer, alongside the EVT801 VEGF receptor inhibitor, the NDL2 nuclear PD-L1 protein degrader, and the MSETC SETDB1-targeted epigenetic platform acquired from QIMR Berghofer.

Is Kazia Therapeutics a public or private company?

Kazia Therapeutics is a public company. It is classified as public and is currently operating.

When was Kazia Therapeutics founded?

Kazia Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Kazia Therapeutics based?

Kazia Therapeutics is headquartered in Hornsby, Australia, in the Oceania region.

How does Kazia Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are Kazia Therapeutics's main competitors?

Direct peers on record are CNS Pharmaceuticals, Novocure, Northwest Biotherapeutics and Denovo Biopharma. Emerging players are Arvinas, Cellectar Biosciences, Cardiff Oncology, VBL Therapeutics, Mustang Bio and Kymera Therapeutics.

Does Kazia Therapeutics have an API?

No public API is recorded for Kazia Therapeutics.

What industry is Kazia Therapeutics in?

Kazia Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanKazia Therapeutics to Host NDL2 Event Dec. 2Kazia Therapeutics will host a virtual event on December 2, 2026, to present its oncology candidate NDL2, a first-in-class nuclear PD-L1 protein degrader. The event will feature management's overview of the candidate.Stock TitanKazia Therapeutics Wins 2026 Drug Discovery AwardKazia Therapeutics was named Drug Discovery Company of the Year in the 2026 BioTech Breakthrough Awards program. The award recognizes the company's drug discovery efforts, with no additional details provided.Stock TitanKazia Therapeutics: 2 paxalisib abstracts accepted at SABCSKazia Therapeutics announced acceptance of two paxalisib research abstracts for poster presentation at the 2026 San Antonio Breast Cancer Symposium. The abstracts cover tumor and immune reprogramming research.TradingViewNeedham initiates coverage of Kazia Therapeutics at Buy, sets price target at $27Needham initiated coverage of Kazia Therapeutics at Buy with a price target of $27. The target implies an upside of 209.6% from the Oct 29 close of $8.72.Stock TitanKazia Therapeutics to Join Guggenheim Fireside ChatKazia Therapeutics will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026. The company's participation is announced in a press release dated October 29, 2026.TradingViewKazia Therapeutics Limited Stock 12‑Month Price Target Raised to $31.83, Implies 308% UpsideAnalysts' average price target for Kazia Therapeutics Limited rose to $31.83 from $31.57, implying about 308% upside from the Oct. 23 closing price. The consensus remains a Buy across six analysts, with forecasts ranging from $25 to $40 per share.TradingViewLeerink Partners initiates coverage of Kazia Therapeutics with Outperform rating, $30 price targetLeerink Partners initiated coverage of Kazia Therapeutics with an Outperform rating and a $30 price target, implying 282.2% upside from the Oct 19 close of $7.85. The rating is based on strong clinical data for Paxalisib in TNBC and GBM, and potential expansion into HR+ breast cancer.AInvestKazia's "First Patient Dosed" Headline Is True. Here Is the Number It Doesn't Move.Kazia Therapeutics' paxalisib was dosed to the first patient in the PNOC035 trial for pediatric AT/RT at UCSF. The milestone is a logistics event, not a data event, and does not advance the drug's efficacy. Kazia's cash position and share dilution remain the key financial concerns.NewswireKazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain CancerKazia Therapeutics announced the first patient dosed in PNOC035, a Phase 2 study of paxalisib plus gemcitabine for recurrent pediatric AT/RT. Preclinical data showed median survival nearly four-fold (22 to 82.5 days). The company may receive a pediatric priority review voucher if approved.PR Newswire APACKazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain CancerKazia Therapeutics announced the first patient dosed in PNOC035, a Phase 2 study of paxalisib plus gemcitabine for recurrent pediatric AT/RT. Preclinical data showed median survival increased from 22 to 82.5 days. The company may become eligible for a pediatric priority review voucher if approved.